ClinicalTrials.gg
WithdrawnNCT04454684MED1Updated Oct 31, 2024

A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders

A Phase 2 interventional study of Midomafetamine and Non-directive therapy in Anorexia Nervosa Restricting Type and Binge-Eating Disorder, sponsored by Lykos Therapeutics. Withdrawn. Open to female participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
No site was initiated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
21 Years to 65 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to learn if MDMA-assisted therapy and caregiver involvement are safe and effective in treating female participants with eating disorders.

The main question it aims to answer is: Does MDMA-assisted therapy reduce eating disorder symptoms?

Participants will undergo two non-drug preparatory therapy sessions and their caregiver will undergo one non-drug preparatory therapy session. Participants will undergo three sessions of MDMA-assisted therapy followed by non-drug integrative therapy sessions alone as well as together with their caregiver.

Read the detailed description

This Phase 2, open-label, multi-site study will explore the safety and feasibility MDMA-assisted psychotherapy and adjunctive caregiver involvement in the treatment of 18 participants with eating disorders. The study will enroll 12 participants with anorexia nervosa restricting-type (AN-R) and six participants with binge eating disorder (BED). A supportive caregiver, such as a parent or partner, for each participant will also be recruited to participate in the study and receive non-drug psychotherapy support.

The study will consist of two Preparatory Sessions for each participant with an eating disorder and one Preparatory Session for each caregiver participant. During the treatment period, participants with eating disorders will undergo three Experimental Sessions of MDMA-assisted psychotherapy, lasting approximately eight hours each. The first Experimental Session will be followed by Individual Integrative Sessions for the participant with an eating disorder and caregiver participant separately as well as a combined Dyadic Integrative Session with both the participant with an eating disorder and their caregiver together. After the second and third Experimental Session, just the participant with an eating disorder will have an Individual Integrative Session before the combined Dyadic Integrative Session with their caregiver.

The first Experimental Session will involve a dose of 80 mg midomafetamine HCl, followed by a supplemental half-dose of 40 mg 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions will involve a flexible dose of 80 or 120 mg of midomafetamine HCl, followed by a supplement half-dose of 40 or 60 mg, respectively, unless contraindicated. The primary outcome measure is the change in Eating Disorder Examination (EDE) results at Baseline to Visit 16 (Study Termination).

02

Conditions studied

  • Anorexia Nervosa Restricting Type
  • Binge-Eating Disorder

Browse trials for

03

In context

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 51 are open to participants now.

Browse Binge-Eating Disorder studies →

Lead sponsor

Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for Eating Disorder (ED) Participants:

  • Are 21 to 65 years old.
  • Are assigned female at birth.
  • Are fluent in speaking and reading the English language and can provide written .
  • Are able to swallow pills.
  • Agree to have study visits recorded to audio and video.
  • Are willing to include a consenting caregiver as a co-participant in elements of the study with whom the study team will have regular contact. This person must be willing and able to be reached by the investigators in case of emergency.
  • If connected to a psychotherapist at the time of recruitment into the study, participants may not change therapists, change the frequency of therapy, or commence any new type of therapy until after the Study Termination Visit, 1 month after the final Experimental Session.
  • Have an identified Primary Care Physician (PCP) and provide consent for the investigator to communicate with PCP, as needed.
  • If AN-R diagnosis, are currently participating in a recognized ED treatment program.
  • Are willing to sign a release for the investigators to communicate directly with their therapist, physician if relevant, as well treatment providers where they were currently or previously engaged an ED-specific episode of treatment.
  • Live within reasonable driving distance of the study site (equal to or less than an estimated 2-hour drive from the study site).
  • If of , must have a negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate
  • Agree to inform the investigators within 48 hours of any medical conditions and procedures.
  • Agree to lifestyle modifications, comply with requirements for fasting and refraining from certain medications prior to Experimental Sessions, not participate in any other interventional clinical trials during the duration of the study, remain overnight at the study site (or appropriate location approved by the research team) after each Experimental Session, not operate a vehicle within 24 hours after MDMA administration, and commit to medication dosing, therapy, and study procedures.
  • Have Anorexia Nervosa, Restricting Type or Binge Eating Disorder.
  • Current or past treatment were not successful to retain remission
  • Have a > 15 kg/m2 and are medically stable according to screening (ECG), blood pressure monitoring, and blood and urine laboratory screening results.

Exclusion Criteria for Eating Disorder (ED) Participants:

  • Are not able to give adequate informed consent.
  • Have any current problem which, in the opinion of the investigator or Medical Monitor, might interfere with participation.
  • Cannot identify a supportive caregiver to participate in the study (or the caregiver does not meet eligibility criteria).
  • Have a blood or needle phobia that interferes with obtaining necessary blood work
  • Have a history of significant medical disorders
  • Have any current problematic patterns of alcohol or other substance use
  • Require use of prohibited concomitant medications for this study, including those that prolong the /QTc interval during Experimental Sessions.
  • Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate.
  • Have uncontrolled hypertension or history of ventricular arrhythmia.
  • Have Wolff-Parkinson-White syndrome or any other accessory pathway.
  • Have a marked Baseline prolongation of QTcF interval (e.g., repeated demonstration of a QTcF interval > 450 ms).
  • Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).
  • Have symptomatic liver disease.
  • Have a history of non-ED-symptom-related hyponatremia or hyperthermia.
  • Are pregnant or nursing, or are persons of childbearing potential who are not practicing (or not willing to practice) an effective means of birth control.
  • Are assessed to be medically unstable

Inclusion Criteria for Caregiver (CG) Participants:

  • Are fluent in speaking and reading the English language and can provide written informed consent.
  • Are at least 18 years old.
  • Are the parent, partner, or other significant caregiver of the ED Participant.
  • Are involved in caregiving at least 2 hours a week (i.e. companionship, meal support, emotional support, driving to appointments, financial support, etc.).
  • Are willing to provide their loved one with meal/symptom support and emotional support throughout the study.
  • Live within reasonable driving distance of the study site
  • If in ongoing psychotherapy at the time participants are recruited into the study, caregiver participants may continue to see their outside therapist during the course of the study. Caregiver participants must sign a release for the investigators to communicate directly with their therapist. CG Participants may not change therapists, increase the frequency of therapy, or commence any new type of therapy until after their Study Termination Visit.
  • Are willing to commit to Preparatory and Integrative Sessions, completion of evaluation instruments and other study procedures, and being contacted for all necessary telephone contacts.
  • Agree to have study visits recorded to audio and video.

Exclusion Criteria for Caregiver (CG) Participants:

  • Have a current eating disorder.
  • Are unable to give adequate informed consent.
  • Report any current problem which in the opinion of the investigator or Medical Monitor might interfere with enrollment or ongoing participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    AN-R: MDMA-assisted Psychotherapy

    Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg midomafetamine HCl followed by a supplemental half-dose of 40 mg midomafetamine HCl 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg midomafetamine HCl followed by a supplemental half-dose of 40 or 80 mg midomafetamine HCl, respectively, 1.5 to 2 hours later, unless contraindicated.

    Drug: Midomafetamine · Behavioral: Non-directive therapy · Behavioral: Therapy

  • Experimental
    BED: MDMA-assisted Psychotherapy

    Three Experimental Sessions of MDMA-assisted psychotherapy. The first Experimental Session involves 80mg midomafetamine HCl followed by a supplemental half-dose of 40 mg midomafetamine HCl 1.5 to 2 hours later, unless contraindicated. The second and third Experimental Sessions involve a flexible dose of 80 or 120 mg of midomafetamine HCl followed by a supplemental half-dose of 40 or 80 mg midomafetamine HCl, respectively, 1.5 to 2 hours later, unless contraindicated.

    Drug: Midomafetamine · Behavioral: Non-directive therapy · Behavioral: Therapy

  • Experimental
    Caregivers: Psychotherapy

    Psychotherapy alone

    Behavioral: Therapy

Interventions

  • Initial dose of 80 or 120 mg midomafetamine HCl administered orally at the start of each of three psychotherapy sessions, followed by a supplemental half-dose of 40 to 60 mg midomafetamine HCl 1.5 to 2.5 hours later, unless contraindicated.

    Also known as: 3,4-methylenedioxymethamphetamine, MDMA, midomafetamine HCl

  • BehavioralNon-directive therapy

    Non-directive therapy will be conducted during Experimental Sessions.

    Also known as: Manualized MDMA-assisted therapy

  • BehavioralTherapy

    Therapy will be conducted during Preparatory Sessions and Integrative Sessions.

06

What researchers measure

Primary outcomes

  1. Change in Eating Disorder Examination Interview (EDE) Global Score from Baseline to Visit 16 (Study Termination)

    The Eating Disorder Examination Interview (EDE) is a semi-structured interview that assesses the frequency of key behavioral features of eating disorders as well as the severity of specific ED psychopathology. The EDE is widely considered to be the gold standard for assessing eating disorder pathology and can detect differences between individuals with anorexia nervosa and binge eating disorder. The EDE consists of four subscales: Restraint, Eating Concern, Shape Concern, and Weight Concern. The interview rates each question based on its frequency in the past month from a score of 0 (feature not present) to 6 (feature present every day). Subscale scores are calculated by totaling the scores in each subscale and dividing by the total number of items in the subscale. The overall or global score is calculated by summing the four subscale scores and dividing by four. The higher the score, the greater the eating disorder severity and frequency.

    Time frame: Baseline to 17 weeks post-enrollment

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Cooper, Z. and C. Fairburn, The eating disorder examination: A semi-structured interview for the assessment of the specific psychopathology of eating disorders. International journal of eating disorders, 1987. 6(1): p. 1-8.
  • Fairburn, C., Z. Cooper, and M. O'Connor, Eating Disorder Examination (Edition 17.0D; April, 2014). 2014: https://www.corc.uk.net/media/1951/ede_170d.pdf.
  • Keel PK, Brown TA. Update on course and outcome in eating disorders. Int J Eat Disord. 2010 Apr;43(3):195-204. doi: 10.1002/eat.20810. PubMed 20186717 ↗

Individual participant data

Plan to share: Yes — We will share outcome data appearing in any published reports upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data and study-related documents will be available wehn all participants have completed the study.

Access criteria: Interested persons should correspond with the central contact for the multi-site study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Aug 2028, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Jul 1, 2020
StartEst.
Feb 2026
Primary completionEst.
Aug 10, 2028
CompletionEst.
Aug 10, 2028
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04454684
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Jul 1, 2020
Start date
Feb 2026 (estimated)
Primary completion
Aug 10, 2028 (estimated)
Completion
Aug 10, 2028 (estimated)
Last update
Oct 31, 2024

Study contacts

Adele Lafrance, PhD
principal investigator · Emotion Science

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion